Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Paliperidone Stories

2010-04-12 07:00:00

WALTHAM, Mass., April 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Janssen's Invega Sustenna earns Decision Resources' proprietary clinical gold standard status for the treatment of schizophrenia in 2013. Invega Sustenna has competitive advantages in safety, tolerability and delivery over current and emerging therapies. "Invega Sustenna, which launched in the second half of 2009, was the...

2010-01-11 20:57:42

A study published today in the Archives of Internal Medicine examines the impact of a safety warning issued by the Food and Drug Administration for commonly prescribed antipsychotic medications. The results show the warnings resulted in a decline in usage among the elderly with dementia, yet raise the question as to whether the FDA's system of communicating these warnings is sufficiently targeted and effective. "Because this medication class has limited evidence of benefit among the elderly...

2010-01-11 20:09:53

The use of atypical antipsychotics to treat elderly patients with dementia appears to have decreased following a 2005 Food and Drug Administration (FDA) advisory regarding the risks of these medications in this population, according to a report in the January 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Clozapine, the first second-generation or "atypical" antipsychotic medication, was introduced in the United States in 1989, according to background information...

2009-12-10 06:57:00

TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week. An estimated one percent of the world's population suffers from schizophrenia - a brain disorder that impairs a person's...

2009-12-02 07:00:00

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new Pharmacor report entitled Schizophrenia finds that the...

2009-08-03 07:09:00

TITUSVILLE, N.J., Aug. 3 /PRNewswire/ -- The U.S. Food and Drug Administration approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults on Friday, July 31, 2009. It is the first once-monthly, long-acting, injectable atypical antipsychotic approved in the U.S. for this use. Janssen((R)), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, will market INVEGA(R) SUSTENNA(TM) in the...

2009-08-01 13:49:30

Invega Sustenna, a longer-acting anti-psychotic medication for schizophrenia, has been approved by the U.S. Food and Drug Administration, its maker says. Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals Inc., said in a release Friday its once-monthly injectable version of the drug paliperidone palmitate became the first of its kind to be approved in the United States. The approval of once-monthly Invega Sustenna will provide healthcare professionals with a treatment option that is,...

2009-07-31 16:18:00

TITUSVILLE, N.J., July 31 /PRNewswire/ -- The U.S. Food and Drug Administration today approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults. It is the first once-monthly, long-acting, injectable atypical antipsychotic approved in the U.S. for this use. Janssen(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, will market INVEGA SUSTENNA in the U.S. An estimated one percent...

2009-07-31 14:20:00

TITUSVILLE, N.J., July 31 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved the first and only antipsychotic for the acute treatment of schizoaffective disorder. INVEGA(R) (paliperidone) extended-release tablets were approved for the acute treatment of schizoaffective disorder either as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants. INVEGA(R) was approved in 2006 for the treatment of schizophrenia. Janssen(R), Division of...

2009-07-23 07:00:00

WALTHAM, Mass., July 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the patient share of Bristol-Myers Squibb/Otsuka's Abilify has grown in the first three lines of therapy since the 2008 analysis of prescribing trends in newly diagnosed schizophrenia patients. Abilify is second to risperidone (Janssen's Risperdal, generics) in first and second lines of therapy and leads other...